

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**  
**Pursuant to Section 13 or Section 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported):** October 18, 2021

---

**AVADEL PHARMACEUTICALS PLC**  
(Exact Name of Registrant as Specified in its Charter)

---

<b>Ireland</b> (State or other jurisdiction of incorporation)	<b>001-37977</b> (Commission File Number)	<b>98-1341933</b> (IRS Employer Identification No.)
<b>10 Earlsfort Terrace</b> <b>Dublin 2, Ireland, D02 T380</b> (Address of principal executive offices)		<b>Not Applicable</b> (Zip Code)

**Registrant's telephone number, including area code:** +353 1 920 1000

**Not Applicable**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
American Depository Shares* Ordinary Shares, nominal value \$0.01 per share**	AVDL N/A	The Nasdaq Global Market

\*American Depository Shares may be evidenced by American Depository Receipts. Each American Depository Share represents one (1) Ordinary Share.

\*\* Not for trading, but only in connection with the listing of American Depository Shares on The Nasdaq Global Market.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 7.01 Regulation FD Disclosure.**

Avadel Pharmaceuticals plc (the “Company”) expects U.S. Patent Application Serial No. 17/231,455, entitled “Methods of Administering Gamma-Hydroxybutyrate Compositions with Divalproex Sodium,” to be published by the U.S. Patent and Trademark Office on October 21, 2021. This application discloses methods of administering gamma-hydroxybutyrate compositions at full dosage amounts even if the patient is also taking divalproex sodium.

*The information furnished under this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.*

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **AVADEL PHARMACEUTICALS PLC**

Date: October 18, 2021

By: /s/ Jerad G. Seurer

Name:Jerad G. Seurer

Title: Vice President, Legal Affairs & Corporate Secretary

---